International Journal of Drug Delivery Technology
Volume 15, Issue 1

Stability Indicating Method Development of Metformin, Teneligliptin and Pioglitazonein Marketed Formulation by HPLC

Parvin Ahamad Shaikh, Neelam Singla

Department of Pharmaceutical Chemistry, Suresh GyanVihar University, Jaipur, Rajasthan, India

Received: 27th Jan, 2025; Revised: 28th Feb, 2025; Accepted: 5th Mar, 2025; Available Online: 25th Mar, 2025 

ABSTRACT

Expansion and validation of a stability-indicating HPLC approach allowed one to simultaneously test metformin (MET), teneligliptin (TNG), and pioglitazone (PGL) in their commercially available pharmaceutical forms.  Techniques were developed to detect active pharmaceutical ingredients (APIs) and any degradation byproducts in settings either acidic, alkaline, oxidative, or photolytic. To evaluate the stability of MET, TNG, and PGL and make sure the technique could extract the medications from their breakdown products, forced degradation studies were conceded out. The ICH guiding principle followed in validation of method. The outcomes demonstrated that the developed method could accurately and sensitively identify and measure the drugs and the products of their degradation.

Under stress, formed degradation products were excellently isolated and measured; therefore, method was found to be robust in several conditions.  This stability-indicating HPLC methodology useful for repetitive quality control and stability analysis of MET, TNG, and PGL in pharmaceutical formulations.

Keywords: Metformin, Teneligliptin, Pioglitazone, Pharmaceutical formulations, Forced degradation, Validation.

How to cite this article: Parvin Ahamad Shaikh, Neelam Singla. Stability Indicating Method Development of Metformin, Teneligliptin and Pioglitazonein Marketed Formulation by HPLC. International Journal of Drug Delivery Technology, 2025;15(1):296-301. doi: 10.25258/ijddt.15.1.41

REFERENCES

  1. Tembhare E, Gupta KR, Umekar MJ. An approach to drug stability studies and shelf-life determination. Archives of Current Research International. 2019 Nov 7;19(1):1-20.
  2. Alothman ZA, Rahman N, Siddiqui MR. Review on pharmaceutical impurities, stability studies and degradation products: an analytical approach. Reviews in Advanced Sciences and Engineering. 2013 Jun 1;2(2):155-66.
  3. Maggio RM, Vignaduzzo SE, Kaufman TS. Practical and regulatory considerations for stability-indicating methods for the assay of bulk drugs and drug formulations. TrAC Trends in Analytical Chemistry. 2013 Sep 1;49:57-70.
  4. Kumar VN, Konyala SR, Bandaru SS, Puchchakayala G. Comparison of efficacy of add-on therapy of teneligliptin versus pioglitazone among type 2 diabetes mellitus patients ineptly controlled on dual therapy of metformin plus sulfonylurea. Journal of Diabetology. 2019 May 1;10(2):76-82.
  5. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. The American journal of medicine. 1997 Jan 1;102(1):99-110.
  6. Kishimoto M. Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes, metabolic syndrome and obesity: targets and therapy. 2013 May 6:187-95.
  7. Peters AL. Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice. American Journal of Managed care. 2001 Apr 1;7(3; SUPP):S87-95.
  8. Janga KY, King T, Ji N, Sarabu S, Shadambikar G, Sawant S, Xu P, Repka MA, Murthy SN. Photostability issues in pharmaceutical dosage forms and photostabilization. AAPS PharmSciTech. 2018 Jan;19:48-59.
  9. Deshpande M, Shaikh F, Sable V, Patil K, Holam M, Tare H. New Stability Indicating RP-HPLC Method for Estimation of the Drug Molnupiravir. International Journal of Pharmaceutical Quality Assurance. 2023;14(1):149-158.
  10. Alothman ZA, Rahman N, Siddiqui MR. Review on pharmaceutical impurities, stability studies and degradation products: an analytical approach. Reviews in Advanced Sciences and Engineering. 2013 Jun 1;2(2):155-66.
  11. Peraman R, Gowra CS, Reddy YP, Peruru KK. Stability-indicating RP-HPLC method for simultaneous determination of metformin hydrochloride and sitagliptin phosphate in dosage forms. Chromatographia. 2013 Sep;76(17):1153-62.
  12. Vetapalem R, Yejella RP, Atmakuri LR. Development and validation of a stability indicating RP-HPLC method for simultaneous estimation of teneligliptin and metformin. Turkish journal of pharmaceutical sciences. 2020 Apr;17(2):141.
  13. Vaingankar PN, Amin PD. Development and validation of stability-indicating RP-HPLC method for simultaneous determination of metformin HCI and glimepiride in fixed-dose combination. AnAlyticAl chemistry insights. 2016 Jan;11:ACI-S38137.
  14. Dixon JR. The international conference on harmonization good clinical practice guideline. Quality Assurance. 1999 Feb 1;6(2):65-74.
  15. Ahmad S, Ashwin B, Rahman BA, Gorad RU, Tare H. Quality by design (QBD) approach to develop stability indicating RP-HPLC method development for naproxen and pantoprazole. International journal of health sciences. 2022;6:11450-65.
  16. Chandra A, Rana J, Li Y. Separation, identification, quantification, and method validation of anthocyanins in botanical supplement raw materials by HPLC and HPLC− MS. Journal of agricultural and food chemistry. 2001 Aug 20;49(8):3515-21.
  17. Mane VA, Killedar SU, More HA, Gaikwad AS, Tare HA. A novel RP-HPLC gradient elution technique for bioanalytical method development and validation for estimating gallic acid in wistar rat plasma. Int J App Pharm. 2023 Mar 7;15(2):153-60.
  18. Pund S, Nalawade S, Rajurkar V, Jayatpal S, Deshmukh N, Tare H. A brief review on recent advances in reverse phase HPLC. Multidisciplinary Reviews. 2024 Jan 18;7(4):2024072-.
  19. Agrahari V, Bajpai M, Nanda S. Essential concepts of mobile phase selection for reversed phase HPLC. Research Journal of Pharmacy and Technology. 2013;6(5):459-64.
  20. Scrivens G. ICH Q1E Evaluation for stability data. ICH Quality Guidelines: An Implementation Guide. 2017 Sep 27:89-125.